Cover Image
市場調查報告書

醫療設備龍頭企業系列:體外診斷 (IVD) 領域的主要企業:2017年∼2027年

Medical Devices Leader Series - Top In Vitro Diagnostics (IVD) Companies 2017-2027: Leading IVD Companies in the US, Europe and Asia

出版商 Visiongain Ltd 商品編碼 264338
出版日期 內容資訊 英文 185 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
醫療設備龍頭企業系列:體外診斷 (IVD) 領域的主要企業:2017年∼2027年 Medical Devices Leader Series - Top In Vitro Diagnostics (IVD) Companies 2017-2027: Leading IVD Companies in the US, Europe and Asia
出版日期: 2016年11月18日 內容資訊: 英文 185 Pages
簡介

本報告提供今後10年的體外診斷 (IVD) 產業的展望探討,其市場趨勢與主要IVD設備製造企業分析,其發展前途與競爭環境的驗證與評價的獨有最新調查資訊。

第1章 報告概要

第2章 體外診斷 (IVD)的簡介

  • IVD市場
  • 所謂IVD檢驗
  • IVD的分類
    • 美國的分類
    • 歐洲 (EC)的分類
    • IVD市場上法規問題
  • IVD檢驗的種類
    • 照護現場 (POC) 診斷
    • 臨床化學
    • 微生物學
    • 血液學
    • 免疫化學
    • 遺傳基因檢驗
  • 體外診斷市場整體收益預測
    • 市場推動要素
    • 阻礙市場要素
    • IVD產業的未來
  • 企業比較
    • 專門化市場
    • 體外診斷市場上的主要企業

第3章 美國的主要體外診斷設備企業

  • Danaher
  • Abbott Laboratories
  • Johnson & Johnson (J&J)
  • Bio-Rad
  • Becton Dickinson
  • Thermo Fisher Scientific

第4章 歐洲的主要體外診斷設備企業

  • Roche
  • Siemens
  • bioMerieux

第5章 日本的主要體外診斷設備企業

  • Sysmex
  • Arkray

第6章 主要新興體外診斷企業

  • 開發平台及其他企業概要
  • 其他有潛力IVD企業
  • Dako (Agilent Technologies)
  • Genomic Health
  • Laboratory Corporation of America (LabCorp)
  • Recent M&A Activity and Other Key Developments
  • MDxHealth
  • Myriad Genetics
  • QIAGEN

第7章 結論

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0152

What does the future hold for companies of the in vitro diagnostics (IVD) industry? Visiongain's new report Medical Devices Leader Series - Top In Vitro Diagnostics (IVD) Companies 2017-2027: Leading IVD Companies in the US, Europe and Asia shows you the prospects of leading IVD companies to 2027.

Visiongain predicts total revenues the global IVD market will grow from its 2016 level of $61.85bn to $122.9bn by 2027, representing a CAGR of 6.4% during the period 2016 to 2027.

Our report forecasts to 2027 the overarching IVD market and its main segments:

  • Point-of-care (POC) tests
  • Clinical chemistry
  • Immunochemistry
  • Haematological diagnostics
  • Microbiological applications
  • Genetic testing agents
  • Other products

This report provides profiles, discussions and financial analyses - including revenue forecasts to 2027 - for top US IVD companies:

  • Danaher
  • Abbott Laboratories
  • Johnson & Johnson (J&J)
  • Bio-Rad
  • Becton Dickinson
  • Thermo Fisher Scientific

Our report shows you developments and revenue forecasts to 2027 for leading diagnostics companies based in Europe:

  • Roche
  • Siemens
  • bioMérieux

This report also provides outlooks and revenue forecasts to 2027 for top Japanese companies developing and producing IVD tests:

  • Sysmex
  • Arkray

Our work assesses other companies progressing in that field. There you discover activities of these emerging players and their associated organisations:

  • Dako (Agilent Technologies)
  • Genomic Health
  • Laboratory Corporation of America (LabCorp)
  • MDxHealth
  • Myriad Genetics
  • QIAGEN

Our 185 page report provides 65 tables and 75 figures covering 7 different IVD submarkets, leading companies in the US, Europe and Asia.

Discover the most lucrative areas in the industry and the future market prospects. You will see financial results, industry trends, opportunities, and revenue predictions. The increasing prevalence of both chronic and infectious diseases will ensure that there is a great demand for use and innovation of IVDs over the next decade and beyond.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. How This Report Delivers Information
  • 1.2. Main Questions This Report Answers
  • 1.3. Who is This Report For?
  • 1.4. Methods of Research and Analysis
  • 1.5. Frequently Asked Questions (FAQs)
  • 1.6. Some Related Reports
  • 1.7. About Visiongain

2. An Introduction to In Vitro Diagnostics

  • 2.1. The In Vitro Diagnostics Market
    • 2.1.1. The In Vitro Diagnostics Market in 2017
  • 2.2. What are In Vitro Diagnostic (IVD) Tests?
  • 2.3. Classifying In Vitro Diagnostics
    • 2.3.1. The US Classification
    • 2.3.2. The EC (European Commission) Classification
    • 2.3.3. Regulatory Issues in the IVD Market
      • 2.3.3.1. Regulation of IVD Tests
      • 2.3.3.2. Lack of Clarity Can be Costly
  • 2.4. Types of IVD Test
    • 2.4.1. Point of Care Diagnostics
    • 2.4.2. Clinical Chemistry
    • 2.4.3. Microbiology
      • 2.4.3.1. Regulatory Differences with IVD Microbiology Tests
    • 2.4.4. Haematology
    • 2.4.5. Immunochemistry
    • 2.4.6. Genetic Testing
  • 2.5. The IVD Market: Overall Revenue Forecast to 2027
    • 2.5.1. Market Drivers, 2016-2027
    • 2.5.2. Market Restraints, 2016-2027
    • 2.5.3. Future of the IVD Industry
  • 2.6. Company Comparison
    • 2.6.1. Fragmented Market
    • 2.6.2. IVD Market: Leading Manufacturers in 2016

3. The Leading US In Vitro Diagnostic Companies, 2016-2027

  • 3.1. Danaher
    • 3.1.1. Sales and Recent Performance Analysis
    • 3.1.2. Life Sciences and Diagnostics
    • 3.1.3. Key Products
    • 3.1.4. Danaher Manufacturing Capabilities
    • 3.1.5. Danaher IVD Segment: Strengths and Challenges
    • 3.1.6. Danaher's Life Sciences and Diagnostics Revenues
      • 3.1.6.1. IVD Revenue Forecast, 2016-2027
    • 3.1.7. Recent Mergers and Acquisition (M&A) Activity
  • 3.2. Abbott Laboratories
    • 3.2.1. Sales and Recent Performance Analysis
    • 3.2.2. Abbott: Diagnostics Segment
      • 3.2.2.1. In Vitro Diagnostics Products
    • 3.2.3. Abbott IVD Segment: Strengths and Challenges
    • 3.2.4. Abbott Diagnostics Historical Revenues, 2013-2015
    • 3.2.5. IVD Revenue Forecast, 2016-2027
    • 3.2.6. Recent M&A Activity and Strategic Collaborations
      • 3.2.6.1. Collaboration with GSK
      • 3.2.6.2. Collaboration with Merck
      • 3.2.6.3. Acquisition of STARLIMS Technologies
      • 3.2.6.4. Acquisition of Ibis Biosciences, Inc.
    • 3.2.7. Plans to Separate into Two Publicly Traded Companies
  • 3.3. Johnson & Johnson (J&J)
  • 3.4. Bio-Rad
    • 3.4.1. Sales and Recent Performance Analysis
    • 3.4.2. Clinical Diagnostics
      • 3.4.2.1. In Vitro Diagnostics
    • 3.4.3. IVD Revenue 2015
    • 3.4.4. IVD Revenue Forecast, 2017-2026
    • 3.4.5. Recent M&A Activity and Strategic Collaborations
    • 3.4.6. Potential Bio-Rad Labs Takeover Seen in Near-Term
  • 3.5. Becton Dickinson
    • 3.5.1. Global Presence
    • 3.5.2. Distribution
    • 3.5.3. R&D
    • 3.5.4. Sales and Recent Performance Analysis
      • 3.5.4.1. Historical Sales Performance Analysis
    • 3.5.5. BD Diagnostics Revenue
    • 3.5.6. IVD Revenue Forecast, 2017-2027
    • 3.5.7. Recent M&A Activity and Strategic Collaborations
  • 3.6. Thermo Fisher Scientific
    • 3.6.1. Historical Sales and Recent Performance Analysis
    • 3.6.2. Clinical Diagnostics
    • 3.6.3. Key Products
    • 3.6.4. Thermo Fisher's Manufacturing Capabilities
    • 3.6.5. Thermo Fisher's Diagnostics Revenues
    • 3.6.6. IVD Revenue Forecast 2016-2027
    • 3.6.7. Recent Mergers and Acquisition Activity
      • 3.6.7.1. Acquisition of Dionex and Phadia

4. The Leading European In Vitro Diagnostic Companies, 2016-2027

  • 4.1. Roche
    • 4.1.1. Global Presence
    • 4.1.2. Sales and Recent Performance Analysis
    • 4.1.3. Roche Diagnostics
    • 4.1.4. R&D Capabilities
    • 4.1.5. Growing Portfolio of Diagnostic Products
      • 4.1.5.1. Exploring Strategies in the Neurological Sector
    • 4.1.6. IVD Revenue Forecast 2016-2027
    • 4.1.7. Recent M&A Activity and Strategic Collaborations
      • 4.1.7.1. Roche Offers to Acquire Illumina to Strengthen its Leading Position in Diagnostics
  • 4.2. Siemens
    • 4.2.1. Sales and Recent Performance, 2015
    • 4.2.2. Siemens Healthcare
      • 4.2.2.1. Siemens Diagnostics
      • 4.2.2.2. Outperforming the Market
      • 4.2.2.3. In Vitro Diagnostics
    • 4.2.3. IVD Revenue Forecast 2016-2027
    • 4.2.4. Recent M&A Activity and Strategic Collaborations
      • 4.2.4.1. Partnership with ViiV Healthcare
      • 4.2.4.2. Partnership with Tocagen
  • 4.3. bioMérieux
    • 4.3.1. Sales and Recent Performance, 2015
    • 4.3.2. IVD Revenue Forecast 2016-2027
    • 4.3.3. Recent M&A Activity and Strategic Collaborations
      • 4.3.3.1. Partnership with GSK
      • 4.3.3.2. Partnership with Ipsen
      • 4.3.3.3. Partnership with Institute Merieux and Institute Pasteur
      • 4.3.3.4. Collaboration with Hospices Civils de Lyon
      • 4.3.3.5. Acquisition of ARGENE
      • 4.3.3.6. Equity Interest in Knome

5. The Leading Japanese In Vitro Diagnostic Companies, 2016-2027

  • 5.1. Sysmex
    • 5.1.1. Global Presence and Distribution
    • 5.1.2. Sales and Recent Performance Analysis
    • 5.1.3. Sysmex Diagnostics
    • 5.1.4. IVD Revenue Forecast 2016-2027
    • 5.1.5. Recent M&A Activity and Strategic Collaborations
      • 5.1.5.1. Acquisition of Katakura's Research Institute of Biological Science
      • 5.1.5.2. Collaboration with IDEXX Labs to Expand into Animal Diagnostics
  • 5.2. Arkray
    • 5.2.1. Global Presence
    • 5.2.2. R&D
    • 5.2.3. IVD Product Portfolio
    • 5.2.4. Sales and Recent Performance Analysis
    • 5.2.5. IVD Revenue Forecast 2016-2027

6. Emerging In Vitro Diagnostic Companies, 2017

  • 6.1. Pipeline and Other Companies: An Overview, 2017
  • 6.2. Other Prominent In Vitro Diagnostic Players
  • 6.3. Dako (Agilent Technologies)
    • 6.3.1. Sales and Recent Performance Analysis
    • 6.3.2. M&A Activity and Other Key Developments
  • 6.4. Genomic Health
    • 6.4.1. Sales and Recent Performance Analysis
    • 6.4.2. R&D Capabilities
      • 6.4.2.1. TAILORx Clinical Trial
      • 6.4.2.2. RxPonder Trial
      • 6.4.2.3. Partnership with Oncomed
  • 6.5. Laboratory Corporation of America (LabCorp)
    • 6.5.1. Sales and Recent Performance Analysis
    • 6.5.2. In Vitro Diagnostics
  • 6.6. Recent M&A Activity and Other Key Developments
    • 6.6.1. Agreement with Medco Health Sciences
    • 6.6.2. Acquisition of Monogram Biosciences
    • 6.6.3. Non-Exclusive License Agreement with Merck
    • 6.6.4. Acquisition of Genzyme Genetics
    • 6.6.5. Partnership with ARCA Biopharma
  • 6.7. MDxHealth
    • 6.7.1. Sales and Recent Performance Analysis, 2015
    • 6.7.2. R&D Capabilities
    • 6.7.3. In Vitro Diagnostics
      • 6.7.3.1. PharmacoMDx
      • 6.7.3.2. PredictMDx for Brain Cancer
      • 6.7.3.3. PredictMDx for Colon Cancer
      • 6.7.3.4. Partnership with GSK
  • 6.8. Myriad Genetics
    • 6.8.1. Sales and Recent Performance Analysis
    • 6.8.2. R&D Capabilities
    • 6.8.3. In Vitro Diagnostics
  • 6.8.3.1. Myriad RBM
    • 6.8.4. M&A Activity and Recent Partnerships
      • 6.8.4.1. Agreement with BioMarin Pharmaceutical
      • 6.8.4.2. Acquisition of Myriad RBM
      • 6.8.4.3. Strategic Debt Investment in Crescendo Bioscience
      • 6.8.4.4. Agreement with Cephalon
      • 6.8.4.5. Agreement with PharmaMar
  • 6.9. QIAGEN
    • 6.9.1. Sales and Recent Performance Analysis
    • 6.9.2. Continued Expansion in the Emerging Markets
    • 6.9.3. R&D Capabilities
      • 6.9.3.1. More than 15 Projects to Co-Develop and Market Diagnostic Products
      • 6.9.3.2. Provider of Choice for Molecular Diagnostic Tools
    • 6.9.4. Recent M&A Activity and Other Developments
      • 6.9.4.1. Acquisition of Cellestis Ltd.
      • 6.9.4.2. Acquisition of Ipsogen
      • 6.9.4.3. Partnership with Pfizer
      • 6.9.4.4. Partnership with Eli Lilly
      • 6.9.4.5. Acquisition of SABiosciences Corporation
      • 6.9.4.6. Acquisition of DxS Ltd (Now QIAGEN Manchester)
      • 6.9.4.7. Acquisition of Explera s.r.l

7. Conclusions

  • 7.1. In Vitro Diagnostics: Attractive Segment of the Healthcare Market
  • 7.2. Big Pharma Dominated the IVD Market in 2015
  • 7.3. The Rise of ‘Generic Medical Devices'
  • 7.4. What Will Succeed in the IVD Market?
  • 7.5. Small Companies Can Have a Big Impact on the Industry and Market to 2027
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

Table of Figures

  • Figure 2.1: IVD Market ($bn) by Class 2017
  • Figure 2.2: IVD: Overall Market ($bn) Forecast , 2016, 2017, 2021 & 2027
  • Figure 2.3: IVD Market: Drivers and Restraints, 2016-2027
  • Figure 2.4: Leading Companies in the IVD Market: Net Sales ($bn), 2016
  • Figure 2.5: Leading Companies in the IVD Industry: Market Shares (%), 2016
  • Figure 3.1: Danaher: Net Sales ($bn) by Business Segment, 2015
  • Figure 3.2: Danaher: Revenue Shares (%) by Business Segment, 2015
  • Figure 3.3: Danaher: IVD Revenue ($bn) Forecast, AGR (%), 2016-2027
  • Figure 3.4: Danaher: IVD Market Share (%), 2016-2027
  • Figure 3.5: Abbott: Net Sales ($bn) by Business Segment, 2015
  • Figure 3.6: Abbott: Revenue Shares (%) by Business Segment, 2015
  • Figure 3.7: Abbott IVD Historical Performance 2012-2015: Revenue ($bn), AGR (%)
  • Figure 3.8: Abbott: Revenues ($bn) by Region, 2015
  • Figure 3.9: Abbott: Revenue Shares (%) by Region, 2015
  • Figure 3.10: Abbott: IVD Revenue ($bn) Forecast, AGR (%), 2016-2027
  • Figure 3.11: Abbott: IVD Market Share (%), 2016-2027
  • Figure 3.12: Bio-Rad: Historical Diagnostics Revenues ($bn), AGR (%), 2013-2015
  • Figure 3.13: Bio-Rad: Revenue Shares (%) by Business Segment, 2015
  • Figure 3.14: Bio-Rad: Revenue Shares (%) by Region, 2015
  • Figure 3.15: Bio-Rad: IVD Revenue Forecast ($bn), AGR (%), 2016-2027
  • Figure 3.16: Bio-Rad: IVD Market Share (%), 2016-2027
  • Figure 3.17: BD: Company Revenue ($bn), 2013-2015
  • Figure 3.18: BD IVD Revenue Forecast ($bn), AGR (%), 2016-2027
  • Figure 3.19: BD: IVD Market Share (%), 2016-2027
  • Figure 3.20: Thermo Fisher: IVD Net Sales ($bn), 2013-2015
  • Figure 3.21: Thermo Fisher: Revenue Shares (%) by Sector, 2015
  • Figure 3.22: Thermo Fisher: IVD Revenue ($bn) Forecast, AGR (%), 2016-2027
  • Figure 3.23: Thermo Fisher: IVD Market Share (%), 2016-2027
  • Figure 3.24: Thermo Fisher: Mergers & Acquisitions
  • Figure 4.1: Roche: Revenues ($bn) by Sector, 2015
  • Figure 4.2: Roche: Revenue Shares (%) by Sector, 2015
  • Figure 4.3: Roche Diagnostics: Revenue Shares (%) by Region, 2015
  • Figure 4.4: Roche Diagnostics: Revenues ($bn) by Sector, 2015
  • Figure 4.5: Roche Diagnostics: Revenue Shares (%) by Sector, 2015
  • Figure 4.6: Roche: IVD Revenue ($bn), AGR (%), Forecast, 2016-2027
  • Figure 4.7: Roche: IVD Market Share (%), 2016-2027
  • Figure 4.8: Siemens: Revenue Shares (%) by Sector, 2015
  • Figure 4.9: Siemens Healthcare: Revenue Shares (%) by Region, 2015
  • Figure 4.10: Siemens: IVD Revenue ($bn), AGR (%), Forecast 2016-2027
  • Figure 4.11: Siemens: IVD Market Share (%), 2015-2027
  • Figure 4.12: bioMérieux: Revenue ($bn) by Sector, 2015
  • Figure 4.13: bioMérieux: Revenue Shares (%) by Sector, 2015
  • Figure 4.14: bioMérieux: Clinical Applications Revenue ($bn) by Sector, 2015
  • Figure 4.15: bioMérieux: Clinical Applications Revenue Shares (%) by Sector, 2015
  • Figure 4.16: bioMérieux: IVD Revenue ($bn), AGR (%), Forecast, 2016-2027
  • Figure 4.17: bioMérieux: IVD Market Share (%), 2016-2027
  • Figure 5.1: Sysmex: Revenues ($m) by Sector, 2015
  • Figure 5.2: Sysmex: Revenue Shares (%) by Sector, 2015
  • Figure 5.3: Sysmex: Net Sales (%) by Geographical Region, 2015
  • Figure 5.4: Sysmex: IVD Revenue ($bn) Forecast, AGR (%), 2016-2027
  • Figure 5.5: Sysmex: IVD Market Share (%), 2016-2027
  • Figure 5.6: Arkray: IVD Revenue ($bn) Forecast, AGR (%), 2016-2027
  • Figure 5.7: Arkray: IVD Market Share (%), 2015-2027
  • Figure 6.1: Aglient: Revenue ($bn) by Sector, 2015
  • Figure 6.2: Dako: Revenue Shares (%) by Sector, 2015
  • Figure 6.3: Genomic Health: Historical Revenues ($m) and Net Income ($m), 2011-2015
  • Figure 6.4: Genomic Health: Revenue Shares (%) by Reporting Segment, 2015
  • Figure 6.5: Genomic Health: Historical R&D Expense ($m) and R&D as a Percentage of Net Sales (%), 2011-2015
  • Figure 6.6: LabCorp: Historical Revenue ($bn), Profit ($bn), 2011-2015
  • Figure 6.7: LabCorp: Revenues ($bn) by Reporting Segment, 2015
  • Figure 6.8: LabCorp: Revenue Shares (%) by Reporting Segment, 2015
  • Figure 6.9: MDxHealth: Revenues ($m) by Reporting Segment, 2016
  • Figure 6.10: MDxHealth: Revenue Shares (%) by Reporting Segment, 2015
  • Figure 6.11: Myriad: Historical Net Revenues ($m), 2012-2016
  • Figure 6.12: Myriad: Revenue Shares (%) by Sector, 2016
  • Figure 6.13: Myriad Molecular Diagnostics: Revenue Shares (%) by Product, 2016
  • Figure 6.14: Myriad Molecular Diagnostics: Revenue Shares (%) by Sector, 2016
  • Figure 6.15: Myriad: Historical R&D Investments ($m), 2012-2016
  • Figure 6.16: QIAGEN: Historical Revenue ($m), Net Income ($m), 2011-2015
  • Figure 6.16: QIAGEN: Revenues ($m) by Customer Class, 2015
  • Figure 6.17: QIAGEN: Revenue Shares (%) by Customer Class, 2015
  • Figure 6.18: QIAGEN: Revenue Shares (%) by Region, 2015
  • Figure 6.19: QIAGEN: Historical R&D Expense ($m) and R&D Expense as a Percentage of Net Revenue (%), 2013-2015
  • Figure 7.1: IVD Market: Overall World Revenue ($bn), (AGR%) 2016-2027
  • Figure 7.2: Leading Market Segment: Revenue ($bn) Forecasts, 2016-2027

List of Tables

  • Table 2.1: IVD Revenues ($bn) and Market Shares (%) by Class, 2016-2017
  • Table 2.2: Advantages and Disadvantages of POC Diagnostics
  • Table 2.3: IVD Tests: Overall World Market and Submarket Revenue Forecasts ($bn), 2016, 2017, 2021 & 2027
  • Table 2.4: Leading Manufacturers: IVD Market Share (%), 2016
  • Table 2.5: Leading Companies in the IVD Market: Net Sales ($bn) and Market Shares (%), 2016
  • Table 3.1: Danaher: Key Facts, 2016
  • Table 3.2: Danaher: Net Sales ($bn) and Revenue Shares (%) by Business Segment, 2015
  • Table 3.3: Danaher: Life Sciences & Diagnostics Revenue ($bn), AGR (%) 2013-2015
  • Table 3.4: Danaher: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2016-2027
  • Table 3.5: Abbott: Key Facts, 2016
  • Table 3.6: Abbott: Net Sales ($bn) and Revenue Shares (%) by Business Segment, 2015
  • Table 3.7: Abbott: Revenues ($bn) and Revenue Shares (%) by Geographical Region, 2015
  • Table 3.8: Abbott: Diagnostics Revenue ($bn), AGR (%), 2013-2015
  • Table 3.9: Abbott: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2016-2027
  • Table 3.10: Johnson & Johnson: Key Facts, 2016
  • Table 3.11: Bio-Rad: Key Facts, 2017
  • Table 3.12: Bio-Rad: Clinical Diagnostics Revenue ($bn), AGR (%), 2013-2015
  • Table 3.13: Bio-Rad: IVD Revenue Forecast ($bn), Growth (%), CAGR (%), Market Share (%), 2016-2027
  • Table 3.14: BD: Key Facts, 2016
  • Table 3.15: Becton Dickinson: Net Sales ($bn) and Revenue Shares (%) by Sector, 2015
  • Table 3.16: BD: Diagnostics Revenue ($bn), AGR(%), 2013-2015
  • Table 3.17: BD: IVD Revenue Forecast ($bn) Growth (%), CAGR (%), Market Share (%), 2016-2027
  • Table 3.18: Thermo Fisher: Key Facts, 2016
  • Table 3.19: Thermo Fisher: IVD Sales ($bn), AGR (%), 2013-2015
  • Table 3.20: Thermo Fisher: Net Sales ($bn) and Revenue Shares by product segment (%) by Sector, 2015
  • Table 3.21: Thermo Fisher: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2016-2027
  • Table 4.1: Roche: Key Facts, 2016
  • Table 4.2: Roche: Revenue ($bn) and Revenue Shares (%) by Sector, 2015
  • Table 4.3: Roche Diagnostics: Revenue ($bn) and Revenue Shares (%), by Region, 2015
  • Table 4.4: Roche Diagnostics: Revenue ($bn) and Revenue Shares (%) by Sector, 2015
  • Table 4.5: Roche Diagnostics: Marketed Diagnostic Products
  • Table 4.6: Roche: IVD Revenue ($bn) Forecast, Growth (%), CAGR (%), Market Share (%) Forecast 2016-2027
  • Table 4.7: Siemens: Key Facts, 2016
  • Table 4.8: Siemens: Revenue ($bn) and Revenue Shares (%) by Sector, 2015
  • Table 4.9: Siemens: Revenue ($bn) and Revenue Shares (%) by Region, 2015
  • Table 4.10: Siemens: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2016-2027
  • Table 4.11: bioMérieux: Key Facts, 2016
  • Table 4.12: bioMérieux: Revenue ($bn) and Revenue Shares (%) by Sector, 2015
  • Table 4.13: bioMérieux: Clinical Applications Revenue ($bn) and Revenue Shares (%) by Sector, 2015
  • Table 4.14: bioMérieux: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2016-2027
  • Table 5.1: Sysmex: Key Facts, 2016
  • Table 5.2: Sysmex: Revenue ($m) by Sector, 2015
  • Table 5.3: Sysmex: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2016-2027
  • Table 5.4: Arkray: Key Facts, 2016
  • Table 5.5: Arkray: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2016-2027
  • Table 6.1: Aglient: Revenue ($bn) and Revenue Shares (%) by Sector, 2015
  • Table 6.2: Dako: Marketed Diagnostic Products, 2015
  • Table 6.4: Genomic Health: Revenue ($m) and Revenue Shares (%) by Reporting Segment, 2015
  • Table 6.5: Genomic Health: R&D Expense ($m) and R&D Expense as a Percentage of Sales (%), 2011-2015
  • Table 6.6: LabCorp: Revenues ($bn) and Revenue Shares (%) by Reporting Segment, 2015
  • Table 6.7: Selected List of LabCorp's Menu of Diagnostic Products, 2015
  • Table 6.8: MDxHealth: Revenue ($m) and Revenue Shares (%) by Reporting Segment, 2015
  • Table 6.9: MDxHealth: In Vitro Diagnostics Pipeline, 2016
  • Table 6.1: Myriad: Revenue ($m) and Revenue Shares (%) by Sector, 2016
  • Table 6.11: Myriad Molecular Diagnostics: Revenue ($m) and Revenue Shares (%) by Product, 2016
  • Table 6.12: Myriad Molecular Diagnostics: Revenue ($m) and Revenue Shares (%) by Sector, 2016
  • Table 6.13: Myriad: Biomarker Product Portfolio, 2016
  • Table 6.14: Myriad: Diagnostic Products, 2016
  • Table 6.15: QIAGEN: Revenue ($m) and Revenue Shares (%) by Customer Class, 2015
  • Table 6.16: QIAGEN: Revenue ($m) and Revenue Shares (%) by Region, 2015
  • Table 6.17: QIAGEN: Selected List of Co-development Projects
  • Table 6.18: QIAGEN: Selected Marketed Diagnostic Products, 2015
  • Table 6.19: QIAGEN: Recent M&A Activity
  • Table 6.22: Other Companies Operating in the IVD Market, 2016
  • Table 7.1: Leading IVD Manufacturers by Company Type, 2016

Companies Listed

  • 3M
  • AB Sciex
  • Abbott Laboratories
  • AbbVie
  • Accuri Cytometers
  • Agilent Technologies
  • Alacris Theranostics GmbH
  • Alere
  • Amgen
  • Analytical Technologies
  • ARGENE
  • Arkray
  • AstraZeneca
  • Banner Alzheimer's Institute
  • Bayer
  • Bayer Diagnostics
  • BD Pharmaceutical Systems
  • BD Technologies
  • Beckman Coulter
  • Becton, Dickinson and Company (BD)
  • BioMarin Pharmaceutical
  • bioMérieux
  • Bio-Rad
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cancer Research Technology
  • Cardiogenics
  • Carmel Pharma AB
  • Celldex Therapeutics
  • Cellestis
  • Centre for Devices and Radiological Health (CDRH)
  • Cephalon
  • Claros Diagnostics
  • Clearstone Central Laboratories
  • CLIA laboratory
  • Clovis
  • Cole-Parmer
  • Crescendo Bioscience
  • Dako (Agilent Technologies)
  • Danaher
  • Dionex
  • DxS (Now QIAGEN Manchester)
  • Eli Lilly
  • ESE GmbH
  • Euronext Brussels
  • European Commission
  • European Diagnostic Manufacturers Association (EDMA)
  • European Union (EU)
  • Explera s.r.l
  • Fermentas
  • Fisher Scientific
  • Food and Drug Administration (US FDA)
  • Fujirebio
  • Furuno Electric Co.
  • Genentech
  • Genomic Health
  • GenProbe
  • Genzyme Genetics
  • GlaxoSmithKline (GSK)
  • Hoffman La Roche
  • Hologic
  • Ibis Biosciences
  • IDEXX Laboratories
  • IGEN International
  • Illumina
  • Institut Pasteur
  • Institute Merieux
  • Instrumentation Labs
  • Ipsen
  • Ipsogen
  • JEOL Ltd.
  • John Hopkins University
  • Johnson & Johnson (J&J)
  • Katakura Industries
  • KIESTRA Lab Automation
  • Knome
  • LabCorp
  • Laboratory Corporation of America (LabCorp)
  • Leica Biosystems
  • Life Technologies
  • Luminex
  • Lyon Civil Hospitals
  • MDS
  • MDxHealth
  • Medco Health Sciences
  • Merck & Co.
  • Mindray
  • Miraca Life Sciences
  • Monogram Biosciences
  • Myriad Genetics
  • Myriad RBM
  • Nalgene
  • Newcastle University
  • Novartis
  • Oncomed
  • OncoMethylome
  • Ortho-Clinical Diagnostics
  • Pfizer
  • Phadia
  • Pierce Protein Research
  • Polymedco Inc.
  • QIAGEN
  • QuantaLife
  • Quest Diagnostics
  • Radiometer
  • Response Biomedical Corporation
  • Roche
  • Roche Applied Science
  • Saladax
  • Schering Plough
  • SDIX
  • Siemens Healthcare
  • Sirigen Group Limited
  • STARLIMS Technologies
  • Surgipath
  • SWOG
  • Sysmex Corporation
  • Sysmex Group
  • Teva Pharmaceutical Industries
  • Thermo Fisher Scientific
  • Thermo Scientific
  • TOA Corporation
  • TOA Medical Electronics
  • Tocagen
  • Tosoh
  • Transasia Bio Medicals
  • Van Andel Research Institute
  • Ventana
  • Vermillion
  • ViiV Healthcare
Back to Top